



## Vermont New Product Launch Report

NDC	DRUG PROD DESC	INTRODUCED TO MARKET DATE	WAC AT INTRODUCTION
73473-0302-75	Clindamycin Phosphate External Gel 1 %™ (clindamycin phosphate) 75mL per Bottle	9/17/2021	\$ 888.63
<b>MARKETING PRICING PLAN</b>		<b>MARKETING PRICING NONPUBLIC</b>	
Confidential Trade Secret Information of Solaris Pharma, not for public disclosure: The marketing plans for the launch of Clindamycin Phosphate External Gel 1 %™ includes: This is an ANDA/generic drug which is a direct AB substitution for the branded product. All customer acquisition will be through substitution at the retail pharmacy formularies. Pricing is a discount off of current branded pricing.		Y	
<b>ESTIMATED PATIENTS</b>		<b>BREAKTHROUGH THERAPY INDICATOR</b>	<b>PRIORITY REVIEW INDICATOR</b>
Confidential Trade Secret Information of Solaris Pharma, not for public disclosure: We estimate that there are approximately. Drug is prescribed for acne vulgaris which affects 45 Million people in the US annually. The current market data in the US shows approx. 40,000 units sold so actual users may be limited.		N	N
<b>ACQUISITION DATE</b>	<b>ACQUISITION PRICE</b>	<b>ACQUISITION PRICE NONPUBLIC</b>	<b>ACQUISITION PRICE COMMENT</b>
<b>GENERAL COMMENTS</b>			
None.			